Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

Sep 22 2016

• By Jessica Merrill

chemistry

Related Content

Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds

Jun 17 2015

Neurocrine Gets First Drug For Tardive Dyskinesia To FDA

Aug 30 2016

Teva Makes A Specialty M&A Play In Deal To Buy Auspex

Mar 30 2015

Teva CRL Response For Huntington’s Drug Targeted For September

Aug 04 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Neurocrine Biosciences, Inc.

H. Lundbeck A/S

Auspex Pharmaceuticals, Inc

Additional Topics

Clinical Trials Commercial Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window